临床衰弱量表作为高级别胶质瘤切除术后总生存期预测指标
本研究回顾性分析2015至2020年在本中心接受首次切除的289例高级别胶质瘤患者,术前及术后3-6个月采用Rockwood临床衰弱量表(CFS)和卡氏功能状态量表(KPS)评估。结果显示CFS与KPS强相关,术前CFS每增加1分总生存期(OS)风险比为1.54(95%CI 1.38-1.70;p<0.001),随访时风险比为1.58(95%CI 1.41-1.78;p<0.001),与KPS相当。IDH突变患者术前及随访时CFS和KPS均显著更优(p<0.05)。结论认为CFS似乎是高级别胶质瘤患者功能评估的可靠工具。
要点
- 术前及术后中位衰弱评分为3分(IqR 2-4),对应「管理良好」状态。
- CFS与KPS术前(r=-0.85;p<0.001)及随访时(r=-0.90;p<0.001)强相关。
- 术前CFS每增加1分OS风险比为1.54(95%CI 1.38-1.70;p<0.001),随访时为1.58(95%CI 1.41-1.78;p<0.001)。
核心结论
- CFS似乎是高级别胶质瘤患者功能评估的可靠工具,包含非癌症相关方面,是当代患者评估方法。
- CFS对生存期的预测在手术前后可同等估计。
- IDH突变导致更长生存期和更高功能状态。
研究设计与样本
- 回顾性评估2015至2020年在本中心接受首次切除的高级别胶质瘤患者,共纳入289例。
- 术前及术后3-6个月采用Rockwood临床衰弱量表和卡氏功能状态量表评估患者表现。
主要发现
- 术前及术后中位衰弱评分为3分(IqR 2-4),对应「管理良好」。
- CFS与KPS术前强相关(r=-0.85;p<0.001),随访时强相关(r=-0.90;p<0.001)。
- 术前CFS每增加1分OS风险比为1.54(95%CI 1.38-1.70;p<0.001),随访时为1.58(95%CI 1.41-1.78;p<0.001),与KPS相当。
- IDH突变患者术前及随访时CFS和KPS显著更优(p<0.05)。
- 年龄与功能评分仅轻度相关(r=0.21…0.35;p<0.01),但各自独立预测OS(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Clinical Frailty Scale (CFS) describes the general level of fitness or frailty and is widely used in geriatric medicine, intensive care and orthopaedic surgery. This study was conducted to analyze, whether CFS could be used for patients with high-grade glioma. METHODS: Patients harboring high-grade gliomas, undergoing first resection at our center between 2015 and 2020 were retrospectively evaluated. Patients' performance was assessed using the Rockwood Clinical Frailty Scale and the Karnofsky Performance Scale (KPS) preoperatively and 3-6 months postoperatively. RESULTS: 289 patients were included. Pre- as well as postoperative median frailty was 3 CFS points (IqR 2-4) corresponding to "managing well". CFS strongly correlated with KPS preoperatively (r = - 0.85; p < 0.001) and at the 3-6 months follow-up (r = - 0.90; p < 0.001). The reduction of overall survival (OS) was 54% per point of CFS preoperatively (HR 1.54, CI 95% 1.38-1.70; p < 0.001) and 58% at the follow-up (HR 1.58, CI 95% 1.41-1.78; p < 0.001), comparable to KPS. Patients with IDH mutation showed significantly better preoperative and follow-up CFS and KPS (p < 0.05). Age and performance scores correlated only mildly with each other (r = 0.21…0.35; p < 0.01), but independently predicted OS (p < 0.001 each). CONCLUSION: CFS seems to be a reliable tool for functional assessment of patients suffering from high-grade glioma. CFS includes non-cancer related aspects and therefore is a contemporary approach for patient evaluation. Its projection of survival can be equally estimated before and after surgery. IDH-mutation caused longer survival and higher functionality.
引用
- Klingenschmid J, Krigers A, Pinggera D, et al. The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma. J Neurooncol. 2022. PMID: 35467234. doi:10.1007/s11060-022-04001-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。